High-throughput RNA sequencing transcriptome analysis of ABC-DLBCL reveals several tumor evasion strategies

被引:5
作者
Serrano Lopez, Juana [1 ]
Jimenez-Jimenez, Carla [2 ,3 ]
Chutipongtanate, Somchai [4 ,5 ,6 ,7 ]
Serrano, Josefina [8 ]
Rodriguez-Moreno, Marta [9 ]
Jimenez, Alvaro [10 ]
Jimenez, Yesenia [11 ]
Pedrero, Sara G. [1 ]
Lainez, Daniel [1 ]
Manuel Alonso-Dominguez, Juan [1 ,12 ]
Llamas Sillero, Pilar [1 ,12 ]
Angel Piris, Miguel [9 ]
Sanchez-Garcia, Joaquin [8 ]
机构
[1] UAM, Expt Hematol Lab, IIS Fdn Jimenez Diaz, Madrid, Spain
[2] Univ Complutense Madrid, Inst Invest Sanitaria Hosp 12 Octubre, Sch Pharm, Dept Chem Pharmaceut Sci, Madrid, Spain
[3] CIBER BBN, Networking Res Ctr Bioengn Biomat & Nanomed, Madrid, Spain
[4] Chakri Naruebodindra Med Inst, Dept Pediat, Bangkok, Thailand
[5] Chakri Naruebodindra Med Inst, Dept Clin Epidemiol, Bangkok, Thailand
[6] Chakri Naruebodindra Med Inst, Dept Biostat, Bangkok, Thailand
[7] Mahidol Univ, Ramathibodi Hosp, Fac Med, Bangkok, Thailand
[8] Univ Cordoba, Hematol Dept, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Cordoba, Spain
[9] Fdn Jimenez Diaz, Pathol, Madrid, Spain
[10] Univ Cordoba, Reina Sofia Univ Hosp, IMIBIC Maimonides Biomed Res Inst Cordoba, Genom Unit, Cordoba, Spain
[11] UAM, Immunol Dept, IIS Fdn Jimenez Diaz, Madrid, Spain
[12] Hosp Univ Fdn Jimenez Diaz, Hematol, Madrid, Spain
关键词
RNA-sequencing; ABC-DLBCL; tumor evasion mediators; MAPK10; perturbagens; GENE-EXPRESSION; CELL; MECHANISMS; RESISTANCE; INHIBITOR;
D O I
10.1080/10428194.2022.2056173
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activated B-cell (ABC) lymphoma, a distinct molecular entity within diffuse large B-cell lymphoma (DLBCL), remains highly incurable, showing a worse response to standard immunochemotherapy. The discouraging results obtained in several clinical trials using proteasome inhibitors, tyrosine kinase inhibitors, or immunomodulators, lead to an intense search for new, potentially druggable biomarkers in DLBCL. In this study, we designed an experimental strategy for DLBCL to discover high- and low-abundance RNA-seq-derived transcripts involved in the oncogenic phenotype in patients diagnosed with ABC-DLBCL. Based on the results of a comparative analysis, 79 DE genes and two enriched gene sets related to metabolism and immunity were selected. Genes related to drug resistance, anti-inflammatory response, and tumor-cell dissemination were found to be up-regulated, while tumor suppressor genes were down-regulated. Then, we searched for the perturbagens most suitable for gene expression profiling (GEP) by iLINCS-CMap. Herein, we present a novel experimental approach that connects the omics signature of DLBCL with potential drugs for more accurate treatments.
引用
收藏
页码:1861 / 1870
页数:10
相关论文
共 31 条
[21]  
Pilarczyk M., 2019, CONNECTING OMICS SIG, DOI DOI 10.1101/826271
[22]   The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma [J].
Rosenwald, A ;
Wright, G ;
Chan, WC ;
Connors, JM ;
Campo, E ;
Fisher, RI ;
Gascoyne, RD ;
Muller-Hermelink, HK ;
Smeland, EB ;
Staudt, LM .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (25) :1937-1947
[23]   Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma [J].
Schmitz, R. ;
Wright, G. W. ;
Huang, D. W. ;
Johnson, C. A. ;
Phelan, J. D. ;
Wang, J. Q. ;
Roulland, S. ;
Kasbekar, M. ;
Young, R. M. ;
Shaffer, A. L. ;
Hodson, D. J. ;
Xiao, W. ;
Yu, X. ;
Yang, Y. ;
Zhao, H. ;
Xu, W. ;
Liu, X. ;
Zhou, B. ;
Du, W. ;
Chan, W. C. ;
Jaffe, E. S. ;
Gascoyne, R. D. ;
Connors, J. M. ;
Campo, E. ;
Lopez-Guillermo, A. ;
Rosenwald, A. ;
Ott, G. ;
Delabie, J. ;
Rimsza, L. M. ;
Wei, K. Tay Kuang ;
Zelenetz, A. D. ;
Leonard, J. P. ;
Bartlett, N. L. ;
Tran, B. ;
Shetty, J. ;
Zhao, Y. ;
Soppet, D. R. ;
Pittaluga, S. ;
Wilson, W. H. ;
Staudt, L. M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (15) :1396-1407
[24]   Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies [J].
Scott, David W. ;
Mottok, Anja ;
Ennishi, Daisuke ;
Wright, George W. ;
Farinha, Pedro ;
Ben-Neriah, Susana ;
Kridel, Robert ;
Barry, Garrett S. ;
Hother, Christoffer ;
Abrisqueta, Pau ;
Boyle, Merrill ;
Meissner, Barbara ;
Telenius, Adele ;
Savage, Kerry J. ;
Sehn, Laurie H. ;
Slack, Graham W. ;
Steidl, Christian ;
Staudt, Louis M. ;
Connors, Joseph M. ;
Rimsza, Lisa M. ;
Gascoyne, Randy D. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (26) :2848-+
[25]   Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma [J].
Sehn, Laurie H. ;
Herrera, Alex F. ;
Flowers, Christopher R. ;
Kamdar, Manali K. ;
McMillan, Andrew ;
Hertzberg, Mark ;
Assouline, Sarit ;
Kim, Tae Min ;
Kim, Won Seog ;
Ozcan, Muhit ;
Hirata, Jamie ;
Penuel, Elicia ;
Paulson, Joseph N. ;
Cheng, Ji ;
Ku, Grace ;
Matasar, Matthew J. .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) :155-+
[26]   Genetic lesions in diffuse large B-cell lymphomas [J].
Testoni, M. ;
Zucca, E. ;
Young, K. H. ;
Bertoni, F. .
ANNALS OF ONCOLOGY, 2015, 26 (06) :1069-1080
[27]   ALOX15 as a suppressor of inflammation and cancer: Lost in the link [J].
Tian, Rui ;
Zuo, Xiangsheng ;
Jaoude, Jonathan ;
Mao, Fei ;
Colby, Jennifer ;
Shureiqi, Imad .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2017, 132 :77-83
[28]   The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers [J].
Vinnedge, L. M. Privette ;
Benight, N. M. ;
Wagh, P. K. ;
Pease, N. A. ;
Nashu, M. A. ;
Serrano-Lopez, J. ;
Adams, A. K. ;
Cancelas, J. A. ;
Waltz, S. E. ;
Wells, S. I. .
ONCOGENE, 2015, 34 (18) :2325-2336
[29]   Aggressive B-cell lymphoma: chasing the target [J].
Walewski, Jan .
JOURNAL OF INVESTIGATIVE MEDICINE, 2020, 68 (02) :331-334
[30]   A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma [J].
Wright, G ;
Tan, B ;
Rosenwald, A ;
Hurt, EH ;
Wiestner, A ;
Staudt, LM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (17) :9991-9996